CAJ | 학술논문

目的:探讨胰腺癌患者外周血循环肝细胞生长因子受体 c-Met 和端粒酶亚催化单位(human telomerase reverse tran?scriptase,h-TERT)表达的临床意义.方法:联合应用纳米免疫磁珠及巢式 PCR 方法检测胰腺癌患者外周血循环中 c-Met 和h-TERT的表达以确定微转移是否存在,并探讨其临床意义.结果:胰腺癌患者外周血循环 c-Met 与 h-TERT的表达与性别、年龄、肿瘤大小、血清CA-199及CEA无统计学相关(P>0.05).不同肿瘤分期间c-Met 和h-TERT阳性表达率有显著性差异(P<0.05),外周血c-Met 与h-TERT表达阳性患者有肿瘤复发风险,h-TERT阳性患者较c-Met阳性患者肿瘤复发率高(P<0.05).c-Met表达阳性的患者无瘤生存中位时间为12个月,阴性患者为20个月(P=0.044);h-TERT表达阳性患者无瘤生存中位时间为9个月,阴性患者为15个月(P<0.001).结论:外周血存在微转移的胰腺癌患者肿瘤复发率高,外周血h-TERT较c-Met表达阳性患者肿瘤复发率高,预后更差.
목적:탐토이선암환자외주혈순배간세포생장인자수체 c-Met 화단립매아최화단위(human telomerase reverse tran?scriptase,h-TERT)표체적림상의의.방법:연합응용납미면역자주급소식 PCR 방법검측이선암환자외주혈순배중 c-Met 화h-TERT적표체이학정미전이시부존재,병탐토기림상의의.결과:이선암환자외주혈순배 c-Met 여 h-TERT적표체여성별、년령、종류대소、혈청CA-199급CEA무통계학상관(P>0.05).불동종류분기간c-Met 화h-TERT양성표체솔유현저성차이(P<0.05),외주혈c-Met 여h-TERT표체양성환자유종류복발풍험,h-TERT양성환자교c-Met양성환자종류복발솔고(P<0.05).c-Met표체양성적환자무류생존중위시간위12개월,음성환자위20개월(P=0.044);h-TERT표체양성환자무류생존중위시간위9개월,음성환자위15개월(P<0.001).결론:외주혈존재미전이적이선암환자종류복발솔고,외주혈h-TERT교c-Met표체양성환자종류복발솔고,예후경차.
Objective: This study aimed to investigate the clinical significance of the human telomerase reverse transcriptase (h-TERT) and c-Met gene expressions in the peripheral blood of pancreatic cancer patients. Methods: Magnetic cell sorting and reverse transcription-nest-polymerase chain reaction were performed to detect h-TERT and c-Met expressions in the peripheral blood of pancre-atic cancer and determine whether or not micrometastasis was present. The clinical significance of micrometastasis was analyzed. Re-sults: The positive rates of c-Met and h-TERT did not significantly correlate with gender, age, cancer size, cancer antigen 19-9, and car-cinoembryonic antigen in the serum (P>0.05). The positive rates of c-Met and h-TERT genes in the peripheral blood of pancreatic can-cer patients significantly correlated with TNM staging (P<0.05). The recurrence rate was higher in pancreatic cancer patients with posi-tive h-TERT compared with that in patients with positive c-Met. The median disease-free survival time for patients with positive h-TERT and c-Met was 12 and 9 months, respectively. The median disease-free survival time was 20 months (P=0.044) for patients with negative h-TERT. For pancreatic cancer patients with negative c-Met, the median disease-free survival time was 15 months (P<0.001). Conclusion: The prognosis is poorer in h-TERT-positive patients than in c-Met-positive patients. The relapse rate was higher in h-TERT-positive patients who have poor prognosis.